Descripción del título
Harnessing oncolytic virus-...
Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity
Monografía
monografia Rebiun26190100 https://catalogo.rebiun.org/rebiun/record/Rebiun26190100 m o u cr#||||||||||| 160829s2015 sz a ob 000 u eng d 9782889193080 ebook) UPVA 998210811303706 UCAR 991007754648104213 CBUC 991009432597006719 CBUC 991004263040406713 CBUC 991013268728806708 CBUC 991010353828106709 CBUC 991000712365106712 PQKB eng UkMaJRU rda eng Harnessing oncolytic virus-mediated immunity topic editors: Philippe Fournier and Volker Schirrmacher Switzerland Frontiers Media SA 2015 Switzerland Switzerland Frontiers Media SA 1 online resource (110 pages) illustrations; digital, PDF file(s) 1 online resource (110 pages) Frontiers Research Topics Bibliographic Level Mode of Issuance: Monograph Includes bibliographical references Open Access. Unrestricted online access star Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity Mode of access: internet via World Wide Web English Fournier, Philippe editor Schirrmacher, V editor